Skip to main content
TipRanks
Go Ultimate75% OFF

Relmada Therapeutics (RLMD) Stock Statistics & Valuation Metrics

446 Followers

Total Valuation

Relmada Therapeutics has a market cap or net worth of $449.19M. The enterprise value is $221.77M.

Market Cap
$449.19M
Enterprise Value
$221.77M

Share Statistics

Relmada Therapeutics has 106,694,850 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
106,694,850
Owned by Insiders
3.19%
Owned by Institutions
44.13%

Financial Efficiency

Relmada Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -67.49%.

Return on Equity (ROE)
-0.66
Return on Assets (ROA)
-0.61
Return on Invested Capital (ROIC)
-67.49%
Return on Capital Employed (ROCE)
-0.67
Revenue Per Employee
0
Profits Per Employee
-3.38M
Employee Count
17
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Relmada Therapeutics is -5.69. Relmada Therapeutics’s PEG ratio is -0.05.

PE Ratio
-5.69
PS Ratio
0.00
PB Ratio
2.44
Price to FCF
-8.66
Price to Operating Cash Flow
-9.13
PEG Ratio
-0.05

Income Statement

In the last 12 months, Relmada Therapeutics had revenue of 0 and earned -57.39M in profits. Earnings per share was -1.45.

Revenue
0
Gross Profit
0
Operating Income
-59.10M
Pretax Income
-57.39M
Net Income
-57.39M
EBITDA
-57.39M
Earnings Per Share (EPS)
-1.45

Cash Flow

In the last 12 months, operating cash flow was -51.86M and capital expenditures 0, giving a free cash flow of -51.86M billion.

Operating Cash Flow
-51.86M
Free Cash Flow
-51.86M
Free Cash Flow per Share
-0.46

Dividends & Yields

Relmada Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-11.54%
Earnings Yield
-13.88%

Stock Price Statistics

Beta
1.30
52-Week Price Change
8.51%
50-Day Moving Average
3.77
200-Day Moving Average
5.40
Relative Strength Index (RSI)
59.30
Average Volume (3m)
1.36M

Important Dates

Relmada Therapeutics upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Mar 23, 2027
Ex-Dividend Date
―

Financial Position

Relmada Therapeutics as a current ratio of 14.62, with Debt / Equity ratio of 0.00%

Current Ratio
14.62
Quick Ratio
14.62
Debt to Market Cap
0.00
Net Debt to EBITDA
0.06
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Relmada Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Relmada Therapeutics EV to EBITDA ratio is -6.83, with an EV/FCF ratio of -8.55.

EV to Sales
0.00
EV to EBITDA
-6.83
EV to Free Cash Flow
-8.55
EV to Operating Cash Flow
-8.55

Balance Sheet

Relmada Therapeutics has $202.12M in cash and marketable securities with $0.00 in debt, giving a net cash position of $202.12M billion.

Cash & Marketable Securities
$202.12M
Total Debt
$0.00
Net Cash
$202.12M
Net Cash Per Share
$1.89
Tangible Book Value Per Share
$1.72

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Relmada Therapeutics is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$12.00
Price Target Upside
185.04% Upside
Analyst Consensus
Moderate Buy
Analyst Count
2
Revenue Growth Forecast
―
EPS Growth Forecast
58.31%

Scores

Smart Score
7
AI Score
58